BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.15 USD
+0.11 (1.56%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $7.16 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BCRX 7.15 +0.11(1.56%)
Will BCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCRX
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for BCRX
ORLADEYO® (berotralstat) Approved in Peru
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Recursion Pharmaceuticals (RXRX) and Progyny (PGNY)
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Analysts Offer Insights on Healthcare Companies: Standard BioTools (LAB), BioCryst (BCRX) and Alnylam Pharma (ALNY)